Targeting ferroptosis in metabolic dysfunction-associated steatotic liver disease: From mechanisms to cell type-specific therapeutic strategies (Review)
Metabolic dysfunction-associated steatotic liver disease (MASLD) impacts >30% of the global population. Its progression to metabolic dysfunction-associated steatohepatitis and liver fibrosis is the primary determinant for cirrhosis and hepatocellular carcinoma. Ferroptosis depends on iron and is driven by lipid peroxid...